Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tandem Diabetes Care, Inc. (NASDAQ: TNDM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tandem Diabetes Care is a global insulin delivery and diabetes technology company whose common stock is registered under Section 12(b) of the Exchange Act and listed on the NASDAQ Global Market under the symbol TNDM.
Through this page, users can review current reports on Form 8-K that document material events such as quarterly earnings announcements, regulatory clearances, and board of director changes. Recent 8-K filings referenced by the company include reports on financial results for quarters ended during 2025 and the appointment of a new independent director to the board, along with related committee assignments and compensation details. Other 8-K filings describe FDA 510(k) clearance for the SteadiSet infusion set and similar operational milestones.
In addition to 8-Ks, Tandem Diabetes Care files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detailed information on its insulin delivery systems, financial condition, risk factors, and business strategy. These filings are important for understanding how the company’s pump portfolio, infusion sets, mobile applications, and cloud-based platforms contribute to its overall operations and financial results.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify information on revenue drivers, regulatory developments, and governance matters. The platform also surfaces insider transaction reports on Form 4 when available, allowing investors to monitor share transactions by directors and officers. Real-time updates from the SEC’s EDGAR system ensure that new Tandem Diabetes Care filings appear promptly, while AI-generated explanations make complex regulatory language more accessible.
Tandem Diabetes Care, Inc. (TNDM) reported an equity award to one of its directors on a Form 4. The director received 20,242 restricted stock units (RSUs) on November 7, 2025 under the company’s 2023 Long-Term Incentive Plan.
Each RSU represents a right to receive either one share of Tandem’s common stock or cash, at the company’s discretion, subject to the plan’s terms. The RSUs vest as to 33% of the total award on November 15, 2026, with the remaining units vesting in two equal annual installments after that date, contingent on the applicable conditions being met.
Tandem Diabetes Care, Inc. director Sandra Beaver filed an initial statement of beneficial ownership of securities. As of the event date of 11/07/2025, the filing reports beneficial ownership of 0 shares of common stock of Tandem Diabetes Care, Inc., held directly. The filing also shows no derivative securities, such as options or warrants, currently reported as beneficially owned.
Tandem Diabetes Care Inc. (TNDM) reported equity compensation activity for an executive officer. The EVP & Chief Administrative Officer had restricted stock units (RSUs) convert into common stock on 11/17/2025, with 1,503 and 1,096 RSUs settled into shares at an exercise price of $0.
To cover tax withholding on these vestings, the company withheld 430 and 314 shares at a price of $18.61 per share, and no shares were sold into the market. Following these transactions, the reporting person directly beneficially owned around forty thousand shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care Inc. (TNDM) reported insider equity activity by President & CEO and director John F. Sheridan. On 11/17/2025, restricted stock units (RSUs) granted under the company’s 2023 Long-Term Incentive Plan vested and were settled into common stock at no exercise price.
Following the vesting, 5,472 RSUs and 5,982 RSUs were converted into an equal number of common shares. To cover tax withholding on these RSU vestings, the company withheld 2,779 shares and 3,038 shares at a reference price of $18.61 per share; the filing states that no shares were sold. After these transactions, Sheridan directly owned 117,600 shares of common stock, plus 10,943 RSUs and 35,894 RSUs that remain outstanding and subject to the plan’s vesting schedule.
Tandem Diabetes Care (TNDM) executive vice president and chief strategy officer Elizabeth A. Gasser reported several equity transactions in the company’s stock. She voluntarily disclosed acquiring 586 shares of common stock at $15.59 through the company’s Employee Stock Purchase Plan for the May 16, 2025 to November 17, 2025 purchase period.
On the same date, 1,503 and 1,096 shares of common stock were delivered upon the vesting of previously granted restricted stock units, at an exercise price of $0. To cover tax withholding on these RSU vestings, the company withheld 805 and 587 shares at a price of $18.61 per share; no shares were sold into the market.
Following these transactions, Gasser directly beneficially owns 3,000 shares of Tandem Diabetes Care common stock and indirectly beneficially owns 22,949 shares through The Gasser Family Trust dated September 1, 2011, where she serves as co-trustee. The RSUs were granted under the company’s 2023 Long-Term Incentive Plan and vest over multi-year schedules.
Tandem Diabetes Care (TNDM) Chief Technology Officer Rick A. Carpenter reported several equity transactions involving company stock. He voluntarily disclosed acquiring 339 shares of common stock at $15.59 per share through the company’s Employee Stock Purchase Plan for the period from May 16, 2025 through November 17, 2025.
On the same date, 1,437 and 897 restricted stock units (RSUs) were converted into common shares at a $0 exercise price under the 2023 Long-Term Incentive Plan. To cover taxes on these RSU vestings, the company withheld 730 and 456 shares at a price of $18.61 per share, with no shares sold on the market. After these transactions, Carpenter directly beneficially owned 24,053 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care Inc. (TNDM) reported an insider equity transaction by its EVP & Chief Commercial Officer on a Form 4. On 11/17/2025, 76 restricted stock units (RSUs) were converted to common stock at an exercise price of $0, and 40 shares of common stock were withheld at $18.61 per share to cover tax obligations, with no shares sold on the market. Following these transactions, the officer beneficially owned 32,384 shares of common stock directly and 457 RSUs, subject to the company’s 2023 Long-Term Incentive Plan and a vesting schedule that runs in quarterly installments after an initial vesting on 5/15/2025.
Tandem Diabetes Care, Inc. (TNDM) executive vice president and chief operating officer Jean-Claude Kyrillos reported a routine purchase of company stock. On 11/17/2025, he acquired 160 shares of common stock at a price of $15.59 per share through the Tandem Diabetes Care Inc. Amended and Restated 2013 Employee Stock Purchase Plan for the ESPP purchase period from May 16, 2025 through November 17, 2025. Following this transaction, he beneficially owned 22,544 shares of Tandem Diabetes Care common stock held directly. The transaction is reported as exempt under Rule 16b-3(c), which typically covers certain employee benefit plan-related acquisitions.
Tandem Diabetes Care Inc. (TNDM) reported an insider equity transaction by EVP & Chief Financial Officer Leigh Vosseller on 11/17/2025. The filing shows the exercise of restricted stock units (RSUs), converting 1,503 and 1,496 RSUs into common shares at an exercise price of $0.
To cover tax withholding on these vestings, the company withheld 538 and 536 shares at a price of $18.61 per share, with no open-market sales taking place. After these transactions, Vosseller directly owned 37,648 shares of common stock and an additional 25,580 shares indirectly through the Leigh A. Vosseller Trust.
The Form 4 also notes remaining RSU awards under the company’s 2023 Long-Term Incentive Plan, which continue to vest over time based on previously established schedules.
Tandem Diabetes Care Inc. (TNDM) executive vice president and chief legal officer Shannon M. Hansen reported multiple equity transactions dated 11/17/2025 on a Form 4. Hansen voluntarily reported acquiring 800 shares of common stock through the company’s employee stock purchase plan for the May 16, 2025 to November 17, 2025 purchase period, a transaction noted as exempt under Rule 16b-3(c). Several restricted stock unit (RSU) awards were converted to common stock at a $0 exercise price, while 190, 515 and 393 shares were withheld by the company at $18.61 per share to cover tax obligations, with no market sales. After these transactions, Hansen directly holds 21,474 shares and indirectly holds 1,935 shares through the Shannon M. Hansen Trust.